Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shih-Chang Chuang

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Cancers|August 7, 2021
Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic CancerKung-Kai Kuo, Pi-Jung Hsiao, Wen-Tsan Chang, et al.
Therapeutic Advances in Medical Oncology|November 25, 2021
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based studyTai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, et al.
American Journal of Cancer Research|December 12, 2022
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinomaNai-Jung Chiang, Yan-Shen Shan, Chung-Pin Li, et al.
American Journal of Cancer Research|October 13, 2022
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorinYen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 2, 2024
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancerCheng-Yu Tang, Shih-Hung Yang, Chung-Pin Li, et al.
American Journal of Cancer Research|May 9, 2022
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecanShih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, et al.
Journal of Biomedical Science|February 13, 2024
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in TaiwanSiao Muk Cheng, Yung-Yeh Su, Nai-Jung Chiang, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|February 19, 2022
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorinTai-Jan Chiu, Shih-Hung Yang, Sz-Chi Chiu, et al.
Frontiers in Oncology|July 11, 2022
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter StudyYung-Yeh Su, Nai-Jung Chiang, Chung-Pin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2026
A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDACChia-Ming Yeh, Chih-Chuan Yu, An-Fu Lee, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cancers|August 7, 2021
Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic CancerKung-Kai Kuo, Pi-Jung Hsiao, Wen-Tsan Chang, et al.
Therapeutic Advances in Medical Oncology|November 25, 2021
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based studyTai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, et al.
American Journal of Cancer Research|December 12, 2022
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinomaNai-Jung Chiang, Yan-Shen Shan, Chung-Pin Li, et al.
American Journal of Cancer Research|October 13, 2022
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorinYen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 2, 2024
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancerCheng-Yu Tang, Shih-Hung Yang, Chung-Pin Li, et al.
American Journal of Cancer Research|May 9, 2022
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecanShih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, et al.
Journal of Biomedical Science|February 13, 2024
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in TaiwanSiao Muk Cheng, Yung-Yeh Su, Nai-Jung Chiang, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|February 19, 2022
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorinTai-Jan Chiu, Shih-Hung Yang, Sz-Chi Chiu, et al.
Frontiers in Oncology|July 11, 2022
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter StudyYung-Yeh Su, Nai-Jung Chiang, Chung-Pin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2026
A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDACChia-Ming Yeh, Chih-Chuan Yu, An-Fu Lee, et al.
Pageof 6